Objective To investigate the efficacy and safety of unilateral biportal endoscopic transforaminal lumbar interbody fusion(UBE-TLIF),minimally invasive transforaminal lumbar interbody fusion(MIS-TLIF),and posterior lumbar interbody fusion(PLIF)in patients with lumbar disc degenerative change.Methods The medical records of 101 patients with lumbar disc degenerative change who underwent surgical treatment in our hospital from January 2019 to December 2022 were retrospectively collected,and they were divided into UBE-TLIF group(37 cases),MIS-TLIF group(33 cases)and PLIF group(31 cases)according to types of operation.The operation related indexes,visual analogue scale(VAS),dysfunction and postoperative complications of the three groups were compared.The height of the intervertebral space and the lumbar lordosis angle were measured before and after surgery.Interbody fusion 12 months after surgery were evaluated via Bridwell criteria.Results The duration of operation of UBE-TLIF group was significantly longer than that of MIS-TLIF group and PLIF group,and MIS-TLIF group was significantly longer than that of PLIF group,the differences were statistically significant(P＜0.05);The intraoperative blood loss and postoperative drainage volume in the UBE-TLIF group were significantly less than those in the MIS-TLIF group and PLIF group,and the MIS-TLIF group was significantly less than that in the PLIF group,the postoperative hospital stay in the UBE-TLIF group was significantly shorter than that in the MIS-TLIF group and PLIF group,and the MIS-TLIF group was significantly shorter than that in the PLIF group,the differences were statistically significant(P＜0.05);The VAS of low back pain and leg pain at 1,3,and 12 months after operation in the 3 groups were significantly lower than those before operation(P＜0.05);The VAS of low back pain and leg pain at 1 and 3 months after operation in the UBE-TLIF group was significantly lower than that in the MIS-TLIF group and the PLIF group,and the VAS of low back pain and leg pain in the MIS-TLIF group was significantly lower than that in the PLIF group(P＜0.05);The Oswestry disability index(ODI)at 1,3 and 12 months after operation in the 3 groups was significantly lower than that before operation,and the ODI in UBE-TLIF group was significantly lower than that in MIS-TLIF group and PLIF group at 1 month after operation,the differences were statistically significant(P＜0.05);The intervertebral space height and lumbar lordosis angle at 1,3,and 12 months after operation were significantly bigger than those before operation in 3 groups(P＜0.05);At 12 months after operation,the intervertebral fusion rates of UBE-TLIF group,MIS-TLIF group and PLIF group were 94.59%,93.94%and 93.55%,respectively,showing no significant difference among the 3 groups(P＞0.05);The interbody fusion time in UBE-TLIF group and MIS-TLIF group was significantly shorter than that in PLIF group(P＜0.05);There was no significant difference in the incidence of complications among the three groups(P＞0.05).Conclusion UBE-TLIF,MIS-TLIF and PLIF can all achieve a higher interbody fusion rate in treating lumbar disc degenerative change,and UBE-TLIF and MIS-TLIF cause less serious surgical trauma,while UBE-TLIF outperforms MIS-TLIF in respect of surgical trauma,and sees faster postoperative recovery.

Periodontal bone defects, primarily caused by periodontitis, are highly prevalent in clinical settings and manifest as bone fenestration, dehiscence, or attachment loss, presenting a significant challenge to oral health. In regenerative medicine, harnessing developmental principles for tissue repair offers promising therapeutic potential. Of particular interest is the condensation of progenitor cells, an essential event in organogenesis that has inspired clinically effective cell aggregation approaches in dental regeneration. However, the precise cellular coordination mechanisms during condensation and regeneration remain elusive. Here, taking the tooth as a model organ, we employed single-cell RNA sequencing to dissect the cellular composition and heterogeneity of human dental follicle and dental papilla, revealing a distinct Platelet-derived growth factor receptor alpha (PDGFRA) mesenchymal stem/stromal cell (MSC) population with remarkable odontogenic potential. Interestingly, a reciprocal paracrine interaction between PDGFRA⁺ dental follicle stem cells (DFSCs) and CD31⁺ Endomucin⁺ endothelial cells (ECs) was mediated by Vascular endothelial growth factor A (VEGFA) and Platelet-derived growth factor subunit BB (PDGFBB). This crosstalk not only maintains the functionality of PDGFRA⁺ DFSCs but also drives specialized angiogenesis. In vivo periodontal bone regeneration experiments further reveal that communication between PDGFRA⁺ DFSC aggregates and recipient ECs is essential for effective angiogenic-osteogenic coupling and rapid tissue repair. Collectively, our results unravel the importance of MSC-EC crosstalk mediated by the VEGFA and PDGFBB-PDGFRA reciprocal signaling in orchestrating angiogenesis and osteogenesis. These findings not only establish a framework for deciphering and promoting periodontal bone regeneration in potential clinical applications but also offer insights for future therapeutic strategies in dental or broader regenerative medicine.
Receptor, Platelet-Derived Growth Factor alpha/metabolism* ; Humans ; Neovascularization, Physiologic/physiology* ; Dental Sac/cytology* ; Single-Cell Analysis ; Transcriptome ; Mesenchymal Stem Cells/metabolism* ; Bone Regeneration ; Animals ; Dental Papilla/cytology* ; Periodontium/physiology* ; Stem Cells/metabolism* ; Regeneration ; Angiogenesis

Objective To investigate the efficacy and safety of unilateral biportal endoscopic transforaminal lumbar interbody fusion(UBE-TLIF),minimally invasive transforaminal lumbar interbody fusion(MIS-TLIF),and posterior lumbar interbody fusion(PLIF)in patients with lumbar disc degenerative change.Methods The medical records of 101 patients with lumbar disc degenerative change who underwent surgical treatment in our hospital from January 2019 to December 2022 were retrospectively collected,and they were divided into UBE-TLIF group(37 cases),MIS-TLIF group(33 cases)and PLIF group(31 cases)according to types of operation.The operation related indexes,visual analogue scale(VAS),dysfunction and postoperative complications of the three groups were compared.The height of the intervertebral space and the lumbar lordosis angle were measured before and after surgery.Interbody fusion 12 months after surgery were evaluated via Bridwell criteria.Results The duration of operation of UBE-TLIF group was significantly longer than that of MIS-TLIF group and PLIF group,and MIS-TLIF group was significantly longer than that of PLIF group,the differences were statistically significant(P＜0.05);The intraoperative blood loss and postoperative drainage volume in the UBE-TLIF group were significantly less than those in the MIS-TLIF group and PLIF group,and the MIS-TLIF group was significantly less than that in the PLIF group,the postoperative hospital stay in the UBE-TLIF group was significantly shorter than that in the MIS-TLIF group and PLIF group,and the MIS-TLIF group was significantly shorter than that in the PLIF group,the differences were statistically significant(P＜0.05);The VAS of low back pain and leg pain at 1,3,and 12 months after operation in the 3 groups were significantly lower than those before operation(P＜0.05);The VAS of low back pain and leg pain at 1 and 3 months after operation in the UBE-TLIF group was significantly lower than that in the MIS-TLIF group and the PLIF group,and the VAS of low back pain and leg pain in the MIS-TLIF group was significantly lower than that in the PLIF group(P＜0.05);The Oswestry disability index(ODI)at 1,3 and 12 months after operation in the 3 groups was significantly lower than that before operation,and the ODI in UBE-TLIF group was significantly lower than that in MIS-TLIF group and PLIF group at 1 month after operation,the differences were statistically significant(P＜0.05);The intervertebral space height and lumbar lordosis angle at 1,3,and 12 months after operation were significantly bigger than those before operation in 3 groups(P＜0.05);At 12 months after operation,the intervertebral fusion rates of UBE-TLIF group,MIS-TLIF group and PLIF group were 94.59%,93.94%and 93.55%,respectively,showing no significant difference among the 3 groups(P＞0.05);The interbody fusion time in UBE-TLIF group and MIS-TLIF group was significantly shorter than that in PLIF group(P＜0.05);There was no significant difference in the incidence of complications among the three groups(P＞0.05).Conclusion UBE-TLIF,MIS-TLIF and PLIF can all achieve a higher interbody fusion rate in treating lumbar disc degenerative change,and UBE-TLIF and MIS-TLIF cause less serious surgical trauma,while UBE-TLIF outperforms MIS-TLIF in respect of surgical trauma,and sees faster postoperative recovery.

Objective:To explore the efficacy of adjusting the dose of imatinib dose in the context of therapeutic drug monitoring (TDM) in patients with gastrointestinal stromal tumors (GISTs) who are receiving adjuvant therapy after complete resection of their tumors.Methods:This was a descriptive study. Inclusion criteria were (1) complete surgical resection with a pathological diagnosis of GIST, (2) postoperative adjuvant therapy with imatinib and dosage adjustment, (3) multiple TDM of imatinib, and (4) complete clinical, pathological, and follow-up data. The data of 70 patients with GISTs treated at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2015 and December 2023 were collected retrospectively. The study cohort comprised 15 (21.4%) men and 55 (78.6%) women of median age 60 years (range: 25–82). Of the eligible patients, 49 (70.0%) were at high-risk, 14 (20.0%) at intermediate-risk, six (8.6%) at low-risk, and one (1.4%) at very low risk. Patients were followed up by the gastrointestinal stromal tumor clinic every 2–3 months and their plasma concentrations of imatinib were checked. The dose was adjusted to 300 mg/d or 200 mg/d depending on whether they had had ≥ grade III adverse reactions, and whether the first plasma concentration of imatinib was ≥ 1,500 μg/L or between the expected range of 760 μg/L–1,100 μg/L. Studied indicators included adverse reactions, quality of life before and after dose adjustment, and overall survival and recurrence-free survival (RFS) after dose adjustment.Results:Before dose adjustment, all 70 patients received 400 mg of imatinib daily, with initial TDM values of 1,900 ± 568 μg/L, for a median duration of 8.3 months. After dose adjustment, 60 patients received 300 mg daily, with a TDM of 1,216 ± 350 μg/L, whereas 10 received 200 mg daily, with a TDM of 1,023 ± 269 μg/L. The median duration of treatment after dose adjustment was 23.4 months. Compared with those whose dosages were not adjusted, the incidence of bone marrow suppression was significantly lower (74.3% [52/70] vs. 51.4% [36/70], χ 2=9.202, P=0.010); as were the incidences of edema (95.7% [67/70] vs. 50.0% [35/70], χ 2=40.526, P<0.001); skin reactions (70.0% [49/70] vs. 32.9% [23/70), χ 2=22.495, P<0.001); and gastrointestinal reactions (38.6% [27/70] vs. 10.0% [7/70], χ 2=15.899, P<0.001) in those whose dosages were adjusted. The average total scores for physical health before and after dose adjustment were 76 ± 5 and 88 ± 4, respectively; whereas the mental health scores were 75 ± 6 and 89 ± 4, respectively. The median follow-up period was 36 months (range 6–126). During the first 3 years of follow-up, five high-risk patients with non-gastric GISTs developed recurrences. The 3-year overall survival rate was 100%, and the 3-year RFS rate was 92.8%, high-risk patients having a 3-year RFS rate of 89.8%. Conclusion:The adverse reactions and quality of life of GIST patients with severe adverse reactions to adjuvant imatinib therapy after complete resection can be mitigated by appropriately reducing the dosage of imatinib under the guidance of TDM.

In recent years， transcatheter arterial chemoembolization （TACE） has emerged as a common treatment modality for the treatment of hepatocellular carcinoma （HCC）. However， with the ongoing development of embolic agent techniques， the new advances in microspheres and nanoparticles have brought new hope for improving the efficacy and safety of TACE. This article reviews the latest advances and applications of microspheres and nanoparticles in TACE for HCC. First， this article introduces the background of TACE as a therapeutic approach and the emergence of microsphere and nanoparticle techniques， and then it describes the application of various types of microspheres and nanoparticles in TACE and discusses the requisite attributes of an ideal embolic agents. The article focuses on the advances in material science and engineering， as well as the clinical efficacy of drug-eluting microspheres and nanoparticles versus conventional TACE. Furthermore， it discusses the importance of radiological examination in TACE and summarizes the research advances in the radiopaque and magnetic resonance-visible embolic agents. This article also explores the future development directions and challenges of TACE. It also points out the combination of microspheres and nanoparticles with other treatment modalities， the application of personalized and precision medicine in TACE， and the potential regimen of TACE in clinical translation， and meanwhile， it raises the issues of ethics and regulation that need to be further discussed. It is believed that microspheres and nanoparticles have a potential effect in TACE， which provides a theoretical basis and technical support for innovating HCC treatment regimens and improving the prognosis of patients through TACE interventions.

Healthy lifestyles and good living habits are effective strategies and important approaches to prevent chronic non-communicable diseases. With the development of evidence-based medicine, the evidence translation system has made some achievements in clinical practice. There is, however, no comprehensive, professional and efficient system for translating lifestyle evidence globally. Therefore, the Health Lifestyle Evidence (HLSE) Group of Lanzhou University constructed the HLSE Evidence Translation System (https://hlse.cn/), with the aim of synthesizing, evaluating, translating, and applying lifestyle-related evidence resources. This paper aims to introduce the functional module design of the evidence translation system, the system development process and testing, introduce the interface design and function demonstration, and explain the significance of constructing the HLSE.

To systematically construct a guideline to provide a methodological guide for researchers to develop patient decision aids.

Healthy lifestyles and good living habits are effective strategies and important approaches to prevent chronic non-communicable diseases. With the development of evidence-based medicine, the evidence translation system has made some achievements in clinical practice. There is, however, no comprehensive, professional and efficient system for translating lifestyle evidence globally. Therefore, the Health Lifestyle Evidence (HLSE) Group of Lanzhou University constructed the HLSE Evidence Translation System (https://hlse.cn/), with the aim of synthesizing, evaluating, translating, and applying lifestyle-related evidence resources. This paper aims to introduce the functional module design of the evidence translation system, the system development process and testing, introduce the interface design and function demonstration, and explain the significance of constructing the HLSE.

To systematically construct a guideline to provide a methodological guide for researchers to develop patient decision aids.

Objective:To explore the efficacy of adjusting the dose of imatinib dose in the context of therapeutic drug monitoring (TDM) in patients with gastrointestinal stromal tumors (GISTs) who are receiving adjuvant therapy after complete resection of their tumors.Methods:This was a descriptive study. Inclusion criteria were (1) complete surgical resection with a pathological diagnosis of GIST, (2) postoperative adjuvant therapy with imatinib and dosage adjustment, (3) multiple TDM of imatinib, and (4) complete clinical, pathological, and follow-up data. The data of 70 patients with GISTs treated at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2015 and December 2023 were collected retrospectively. The study cohort comprised 15 (21.4%) men and 55 (78.6%) women of median age 60 years (range: 25–82). Of the eligible patients, 49 (70.0%) were at high-risk, 14 (20.0%) at intermediate-risk, six (8.6%) at low-risk, and one (1.4%) at very low risk. Patients were followed up by the gastrointestinal stromal tumor clinic every 2–3 months and their plasma concentrations of imatinib were checked. The dose was adjusted to 300 mg/d or 200 mg/d depending on whether they had had ≥ grade III adverse reactions, and whether the first plasma concentration of imatinib was ≥ 1,500 μg/L or between the expected range of 760 μg/L–1,100 μg/L. Studied indicators included adverse reactions, quality of life before and after dose adjustment, and overall survival and recurrence-free survival (RFS) after dose adjustment.Results:Before dose adjustment, all 70 patients received 400 mg of imatinib daily, with initial TDM values of 1,900 ± 568 μg/L, for a median duration of 8.3 months. After dose adjustment, 60 patients received 300 mg daily, with a TDM of 1,216 ± 350 μg/L, whereas 10 received 200 mg daily, with a TDM of 1,023 ± 269 μg/L. The median duration of treatment after dose adjustment was 23.4 months. Compared with those whose dosages were not adjusted, the incidence of bone marrow suppression was significantly lower (74.3% [52/70] vs. 51.4% [36/70], χ 2=9.202, P=0.010); as were the incidences of edema (95.7% [67/70] vs. 50.0% [35/70], χ 2=40.526, P<0.001); skin reactions (70.0% [49/70] vs. 32.9% [23/70), χ 2=22.495, P<0.001); and gastrointestinal reactions (38.6% [27/70] vs. 10.0% [7/70], χ 2=15.899, P<0.001) in those whose dosages were adjusted. The average total scores for physical health before and after dose adjustment were 76 ± 5 and 88 ± 4, respectively; whereas the mental health scores were 75 ± 6 and 89 ± 4, respectively. The median follow-up period was 36 months (range 6–126). During the first 3 years of follow-up, five high-risk patients with non-gastric GISTs developed recurrences. The 3-year overall survival rate was 100%, and the 3-year RFS rate was 92.8%, high-risk patients having a 3-year RFS rate of 89.8%. Conclusion:The adverse reactions and quality of life of GIST patients with severe adverse reactions to adjuvant imatinib therapy after complete resection can be mitigated by appropriately reducing the dosage of imatinib under the guidance of TDM.